Skip to main content
Caplight Logo









Carus Bio

Carus Bio

Private
SeoulHealthcare & Life Scienceshttps://carusbio.com/

Last Round

VC Round

Apr 1, 2025

Total Funding Raised

$8.85M

Company Overview

Carus Bio is a biotechnology company that develops a drug delivery platform, BioDrone™, based on cell-derived vesicles for in vivo CAR-T therapies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Non-AI

Keywords

drug delivery platformcell-derived vesiclesCDVstargeted drug deliveryin vivo CAR-Textracellular vesiclesexosome drug deliveryCAR-T therapyvesicle technologybiologics deliverygene therapy deliverybiotech platform licensingcancer therapeuticsmRNA delivery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Carus Bio Comparables

Compare Carus Bio with similar companies based on industry and business-model similarity.

Carus Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ILIAS Biologics Inc.
87%
Evox Therapeutics
87%
VesiCURE Therapeutics
80%

Carus Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundApr 1, 2025
Series BAug 27, 2019
Series ASep 30, 2016

Carus Bio Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 1, 2025

    Raised a VC Round with (주)스마트앤그로스 as an investor.

  • Aug 27, 2019

    $9M round with participation from KCLAVIS Investment and QUAD Investment Management.

Carus Bio Filings

Explore SEC and related filing metadata, where available.

Carus Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Carus Bio's valuation, stock price, and market status.

Is Carus Bio a public or private company?

Carus Bio is a private company.

What is the current stock price of Carus Bio?

Carus Bio is a private company with no public stock price. No recent secondary market data is available.

How much is Carus Bio worth (valuation)?

Valuation information for Carus Bio is not publicly available.

Can I buy Carus Bio stock?

Carus Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Carus Bio's last funding round?

Carus Bio's most recent funding round was VC Round on April 1, 2025.

Who are the main investors in Carus Bio?

Key investors in Carus Bio include (주)스마트앤그로스, DAYLI Partners, KCLAVIS Investment, The Wells Investment, QUAD Investment Management.

Will Carus Bio IPO soon?

No public IPO plans have been announced for Carus Bio.

How can I track Carus Bio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Carus Bio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSeoul
Year Founded2015
Last FundingApr 1, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?